ClinicalTrials.gg
CompletedNCT05787249Updated Oct 2, 2026Results posted

Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts

An interventional study of Patient nudge and Provider nudge in Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Completed at 1 site in United States. Open to female participants aged 40 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Screening

How we know

Updated Oct 2, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,358
Allocation
Randomized
Ages
40 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine — 11 open to participants now, 22 under way, none of them phase 3. Breast Neoplasms · Abramson Cancer Center at Penn Medicine.

Enrollment
6th of 45
1,358 · median 53
Started
2023
with 3 others
No phase
22 of 68
3 open now
Registered
59th of 68
by date

Among the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine, this one is the 6th largest by enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 with no phase, and was the 59th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 74 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine, or all of them as a file.
02

Study summary

The goal of this study is to increase MRI utilization among women with extremely dense breasts. The main question it seeks to answer is whether nudging of the provider, patient, or both increases the uptake of MRI among this group, and whether this effect differs between Black and White women.

Read the detailed description

Women with dense breasts have 3-5-fold increased risk for breast cancer as women without dense breasts. Dense breast tissue can "mask" small tumors, leading to reduced mammography sensitivity. Recent randomized controlled trials demonstrate that supplemental breast MRI screening improves detection of small, invasive cancers that are not detected by mammography. In January 2022, a Pennsylvania law went into effect mandating insurance coverage of supplemental screening for women with extremely dense breasts. Currently only a small fraction of eligible women with extremely dense breasts are receiving supplemental breast MRI screening. Clinical pathways to identify patients who are eligible for insurance coverage of supplemental breast MRI screening and communicate this option to patients and providers are needed to ensure equitable access to supplemental screening. This study therefore proposes a stepped wedge cluster randomized clinical trial to determine whether electronic health record (EHR) and secure text message nudges increase utilization of supplemental breast MRI screening among eligible women with extremely dense breasts.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • Breast density
  • Mammography
04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Patient participants:

Inclusion Criteria:

  • Women aged 40-74
  • Recent non-actionable mammogram of less than 6 months
  • Mammogram performed at Penn Center for Advanced Medicine, Penn Presbyterian Hospital, Pennsylvania Hospital, or Radnor
  • Valid mobile phone number

Exclusion Criteria:

  • Prior history of breast cancer
  • No breast MRI within the past 2 years
  • No prior actionable mammogram within 6 months
  • No recent or concurrent ultrasound

Provider participants:

Inclusion Criteria:

  • Provider needs to have ordered the initial screening mammogram
  • Employed by Penn Health System and access to Penn Chart
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
1,358 participants (actual)

Study arms

  • No intervention
    Usual care (no nudge)

    Usual standard of care, no nudging.

  • Experimental
    Provider nudge only

    Nudge sent to provider through electronic health record (EHR).

    Behavioral: Provider nudge

  • Experimental
    Patient nudge only

    Nudge sent to the patient through text messaging.

    Behavioral: Patient nudge

  • Experimental
    Patient and provider nudge

    Nudge sent to both provider through EHR, and to patient through text messaging.

    Behavioral: Patient nudge · Behavioral: Provider nudge

Interventions

  • BehavioralPatient nudge

    Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts

  • BehavioralProvider nudge

    Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts

06

What researchers measure

Primary outcomes

  1. Number of Patients for Whom Breast MRI Was Ordered and/or Scheduled

    Whether a breast MRI is ordered and/or scheduled within 6 months of the mammogram date

    Time frame: 6 months

Secondary outcomes

  1. Number of Patients for Whom Breast MRI Was Ordered

    Whether an MRI is ordered within 6 months of the mammogram date. Analyzed separately from scheduling.

    Time frame: 6 months

  2. Number of Patients Who Scheduled a Breast MRI

    Whether an MRI is scheduled within 6 months of the mammogram date. Analyzed separately from ordering.

    Time frame: 6 months

  3. Number of Patients Who Completed a Breast MRI

    Whether an MRI is completed within 6 months of the mammogram date

    Time frame: 6 months

  4. False-positive Rate

    False-positive rate among those women who schedule and undergo MRI, defined as the number of patients who received a positive MRI result (i.e., BIRADS score of 4 or 5) but did not have a subsequent cancer diagnosis

    Time frame: 6 months

  5. Cancer Detection Rate

    Cancer detection rate among those women who schedule and undergo MRI

    Time frame: 6 months

07

Results

Posted Oct 2, 2026

Participant flow

A total of 292 clinicians from 33 clinics ordered mammograms for patients accruing to the trial. Clinicians were grouped into 10 clinic groups based on where they saw accrued patients. They were not enrolled themselves or consented; EHR changes were considered standard of practice. Part of the randomization (i.e., clinician nudge activation) occurred at the clinic group level, and another (i.e., independent patient randomization and patient nudge implementation) occurred at the patient level.

Participant flow — Overall Study
MilestoneStep 1: Usual Care (1 Month), Patient Nudge Only (1 Month)Step 2: Usual Care, Patient Nudge (2 Months)Step 3: Usual Care, Patient Nudge (3 Months); Provider Nudge Only, Patient+Provider Nudge (1 Month)Step 4: Usual Care, Patient Nudge (4 Months); Provider Nudge Only, Patient+Provider Nudge (2 Months)Step 5: Usual Care, Patient Nudge (5 Months); Provider Nudge Only, Patient+Provider Nudge (3 Months)Step 6: Usual Care, Patient Nudge (6 Months); Provider Nudge Only, Patient+Provider Nudge (4 Months)Step 7: Usual Care, Patient Nudge (7 Months); Provider Nudge Only, Patient+Provider Nudge (5 Months)Step 8: Usual Care, Patient Nudge (8 Months); Provider Nudge Only, Patient+Provider Nudge (6 Months)Step 9: Usual Care, Patient Nudge (9 Months); Provider Nudge Only, Patient+Provider Nudge (7 Months)Step 10: Usual Care, Patient Nudge (10 Months); Provider Nudge Only, Patient + Provider (8 Months)Step 11: Usual Care, Patient Nudge (11 Months); Provider Nudge Only, Patient + Provider (9 Months)Step 12: Usual Care (12 Months); Provider Nudge Only, Patient + Provider Nudge (10 Months)
Started61123115108971301361051289794164
Completed61123115108971301361051289794164
Not completed000000000000

Outcome measures

PrimaryNumber of Patients for Whom Breast MRI Was Ordered and/or Scheduled

Whether a breast MRI is ordered and/or scheduled within 6 months of the mammogram date

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Patients for Whom Breast MRI Was Ordered and/or Scheduled
ParticipantsUsual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider Nudge
Number of Patients for Whom Breast MRI Was Ordered and/or Scheduled8114593140
SecondaryNumber of Patients for Whom Breast MRI Was Ordered

Whether an MRI is ordered within 6 months of the mammogram date. Analyzed separately from scheduling.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Patients for Whom Breast MRI Was Ordered
ParticipantsUsual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider Nudge
Number of Patients for Whom Breast MRI Was Ordered8114593140
SecondaryNumber of Patients Who Scheduled a Breast MRI

Whether an MRI is scheduled within 6 months of the mammogram date. Analyzed separately from ordering.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Patients Who Scheduled a Breast MRI
ParticipantsUsual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider Nudge
Number of Patients Who Scheduled a Breast MRI56945487
SecondaryNumber of Patients Who Completed a Breast MRI

Whether an MRI is completed within 6 months of the mammogram date

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Patients Who Completed a Breast MRI
ParticipantsUsual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider Nudge
Number of Patients Who Completed a Breast MRI39824373
SecondaryFalse-positive Rate

False-positive rate among those women who schedule and undergo MRI, defined as the number of patients who received a positive MRI result (i.e., BIRADS score of 4 or 5) but did not have a subsequent cancer diagnosis

Time frame:
6 months
Reported as:
Count of participants · Participants
False-positive Rate
ParticipantsUsual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider Nudge
False-positive Rate4201221
SecondaryCancer Detection Rate

Cancer detection rate among those women who schedule and undergo MRI

Time frame:
6 months
Reported as:
Count of participants · Participants
Cancer Detection Rate
ParticipantsUsual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider Nudge
Cancer Detection Rate3300

Adverse events

Collected over Six months following the mammogram. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Usual Care (no Nudge)0/343 (0%)0/343 (0%)0/343 (0%)
Provider Nudge Only0/359 (0%)0/359 (0%)0/359 (0%)
Patient Nudge Only0/345 (0%)0/345 (0%)0/345 (0%)
Patient and Provider Nudge0/311 (0%)0/311 (0%)0/311 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Usual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider NudgeTotal
Mean49.68 ± 9.4449.20 ± 9.1948.83 ± 9.0749.01 ± 9.0749.18 ± 9.19
Sex: Female, Male
Sex: Female, Male(Participants)Usual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider NudgeTotal
Female3433593453111358
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Usual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider NudgeTotal
Hispanic or Latino91871044
Not Hispanic or Latino3323393302991300
Unknown or Not Reported228214
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Usual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider NudgeTotal
American Indian or Alaska Native00101
Asian47554835185
Native Hawaiian or Other Pacific Islander01304
Black or African American51645755227
White228218212199857
More than one race256619
Unknown or Not Reported1516181665
Region of Enrollment
Region of Enrollment(participants)Usual Care (no Nudge)Provider Nudge OnlyPatient Nudge OnlyPatient and Provider NudgeTotal
United States3433593453111358
08

Study locations

1 site
  • University of Pennsylvania
    Bala-Cynwyd, Pennsylvania 19004, United States
09

References and documents

Publications

  • Pettersson A, Graff RE, Ursin G, Santos Silva ID, McCormack V, Baglietto L, Vachon C, Bakker MF, Giles GG, Chia KS, Czene K, Eriksson L, Hall P, Hartman M, Warren RM, Hislop G, Chiarelli AM, Hopper JL, Krishnan K, Li J, Li Q, Pagano I, Rosner BA, Wong CS, Scott C, Stone J, Maskarinec G, Boyd NF, van Gils CH, Tamimi RM. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. 2014 May 10;106(5):dju078. doi: 10.1093/jnci/dju078. PubMed 24816206 ↗
  • Bond-Smith D, Stone J. Methodological Challenges and Updated Findings from a Meta-analysis of the Association between Mammographic Density and Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):22-31. doi: 10.1158/1055-9965.EPI-17-1175. Epub 2018 Sep 11. PubMed 30206060 ↗
  • Comstock CE, Gatsonis C, Newstead GM, Snyder BS, Gareen IF, Bergin JT, Rahbar H, Sung JS, Jacobs C, Harvey JA, Nicholson MH, Ward RC, Holt J, Prather A, Miller KD, Schnall MD, Kuhl CK. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. JAMA. 2020 Feb 25;323(8):746-756. doi: 10.1001/jama.2020.0572. PubMed 32096852 ↗
  • Veenhuizen SGA, de Lange SV, Bakker MF, Pijnappel RM, Mann RM, Monninkhof EM, Emaus MJ, de Koekkoek-Doll PK, Bisschops RHC, Lobbes MBI, de Jong MDF, Duvivier KM, Veltman J, Karssemeijer N, de Koning HJ, van Diest PJ, Mali WPTM, van den Bosch MAAJ, van Gils CH, Veldhuis WB; DENSE Trial Study Group. Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial. Radiology. 2021 May;299(2):278-286. doi: 10.1148/radiol.2021203633. Epub 2021 Mar 16. PubMed 33724062 ↗
  • Weinstein SP, Korhonen K, Cirelli C, Schnall MD, McDonald ES, Pantel AR, Zuckerman S, Borthakur A, Conant EF. Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk. J Clin Oncol. 2020 Nov 20;38(33):3874-3882. doi: 10.1200/JCO.19.02198. Epub 2020 Sep 15. PubMed 32931396 ↗
  • Expert Panel on Breast Imaging; Weinstein SP, Slanetz PJ, Lewin AA, Battaglia T, Chagpar AB, Dayaratna S, Dibble EH, Goel MS, Hayward JH, Kubicky CD, Le-Petross HT, Newell MS, Sanford MF, Scheel JR, Vincoff NS, Yao K, Moy L. ACR Appropriateness Criteria(R) Supplemental Breast Cancer Screening Based on Breast Density. J Am Coll Radiol. 2021 Nov;18(11S):S456-S473. doi: 10.1016/j.jacr.2021.09.002. PubMed 34794600 ↗
  • Wolf, Tom. "Insurance Company Law of 1921 - Coverage for Mammographic Examinations." The Office Website for the Pennsylvania General Assembly, Pennsylvania General Assembly, 2020, https://www.legis.state.pa.us/cfdocs/legis/li/uconsCheck.cfm?yr=2020&sessInd=0&act=52.
  • Niraula S, Biswanger N, Hu P, Lambert P, Decker K. Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers. JAMA Netw Open. 2020 Sep 1;3(9):e2018179. doi: 10.1001/jamanetworkopen.2020.18179. PubMed 32975573 ↗
  • Monsees BS. The Mammography Quality Standards Act. An overview of the regulations and guidance. Radiol Clin North Am. 2000 Jul;38(4):759-72. doi: 10.1016/s0033-8389(05)70199-8. PubMed 10943276 ↗
  • Sedrak MS, Myers JS, Small DS, Nachamkin I, Ziemba JB, Murray D, Kurtzman GW, Zhu J, Wang W, Mincarelli D, Danoski D, Wells BP, Berns JS, Brennan PJ, Hanson CW, Dine CJ, Patel MS. Effect of a Price Transparency Intervention in the Electronic Health Record on Clinician Ordering of Inpatient Laboratory Tests: The PRICE Randomized Clinical Trial. JAMA Intern Med. 2017 Jul 1;177(7):939-945. doi: 10.1001/jamainternmed.2017.1144. PubMed 28430829 ↗
  • Patel MS, Kurtzman GW, Kannan S, Small DS, Morris A, Honeywell S Jr, Leri D, Rareshide CAL, Day SC, Mahoney KB, Volpp KG, Asch DA. Effect of an Automated Patient Dashboard Using Active Choice and Peer Comparison Performance Feedback to Physicians on Statin Prescribing: The PRESCRIBE Cluster Randomized Clinical Trial. JAMA Netw Open. 2018 Jul 6;1(3):e180818. doi: 10.1001/jamanetworkopen.2018.0818. PubMed 30646039 ↗
  • Takvorian SU, Bekelman J, Beidas RS, Schnoll R, Clifton ABW, Salam T, Gabriel P, Wileyto EP, Scott CA, Asch DA, Buttenheim AM, Rendle KA, Chaiyachati K, Shelton RC, Ware S, Chivers C, Schuchter LM, Kumar P, Shulman LN, O'Connor N, Lieberman A, Zentgraf K, Parikh RB. Behavioral economic implementation strategies to improve serious illness communication between clinicians and high-risk patients with cancer: protocol for a cluster randomized pragmatic trial. Implement Sci. 2021 Sep 25;16(1):90. doi: 10.1186/s13012-021-01156-6. PubMed 34563227 ↗
  • Jenssen BP, Schnoll R, Beidas R, Bekelman J, Bauer AM, Scott C, Evers-Casey S, Nicoloso J, Gabriel P, Asch DA, Buttenheim A, Chen J, Melo J, Shulman LN, Clifton ABW, Lieberman A, Salam T, Zentgraf K, Rendle KA, Chaiyachati K, Shelton R, Wileyto EP, Ware S, Leone F. Rationale and protocol for a cluster randomized pragmatic clinical trial testing behavioral economic implementation strategies to improve tobacco treatment rates for cancer patients who smoke. Implement Sci. 2021 Jul 15;16(1):72. doi: 10.1186/s13012-021-01139-7. PubMed 34266468 ↗
  • McCarthy AM, Fernandez Perez C, Beidas RS, Bekelman JE, Blumenthal D, Mack E, Bauer AM, Ehsan S, Conant EF, Wheeler BC, Guerra CE, Nunes LW, Gabriel P, Doucette A, Wileyto EP, Buttenheim AM, Asch DA, Rendle KA, Shelton RC, Fayanju OM, Ware S, Plag M, Hyland S, Gionta T, Shulman LN, Schnoll R. Protocol for a pragmatic stepped wedge cluster randomized clinical trial testing behavioral economic implementation strategies to increase supplemental breast MRI screening among patients with extremely dense breasts. Implement Sci. 2023 Nov 24;18(1):65. doi: 10.1186/s13012-023-01323-x. PubMed 38001506 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Apr 2025, 18 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 18 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2023
First posted
Mar 28, 2023
StartActual
Oct 4, 2023
Primary completionActual
Apr 4, 2025
CompletionActual
Apr 4, 2025
Results first posted
Oct 2, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Ordering and/or scheduling of supplemental breast MRINow Number of Patients for Whom Breast MRI Was Ordered and/or ScheduledTime frame: 6 months
Oct 2, 2026
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedOrderingNumber of breastPatients Who Scheduled a Breast MRITime frame: 6 months
  • EditedSchedulingNumber of breastPatients Who Completed a Breast MRITime frame: 6 months
  • EditedFalse-positive rateRateTime frame: 6 months
  • EditedCancer detection rateDetection RateTime frame: 6 months
  • ChangedBefore Completion of breast MRINow Number of Patients for Whom Breast MRI Was OrderedTime frame: 6 months
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Ordering and/or scheduling of supplemental breast MRINow Number of Patients for Whom Breast MRI Was Ordered and/or ScheduledTime frame: 6 months
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedOrderingNumber of breastPatients Who Scheduled a Breast MRITime frame: 6 months
    • EditedSchedulingNumber of breastPatients Who Completed a Breast MRITime frame: 6 months
    • EditedFalse-positive rateRateTime frame: 6 months
    • EditedCancer detection rateDetection RateTime frame: 6 months
    • ChangedBefore Completion of breast MRINow Number of Patients for Whom Breast MRI Was OrderedTime frame: 6 months
    + 4 other changes: index terms, design details, arm descriptions and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05787249
Responsible party
Sponsor
First posted
Mar 28, 2023
Start date
Oct 4, 2023
Primary completion
Apr 4, 2025
Completion
Apr 4, 2025
Results posted
Oct 2, 2026
Last update
Oct 2, 2026

Study contacts

Anne Marie McCarthy, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion